Chewpod introduces energy, sleep supplements as functional gum
Chewpod, a functional gum looking to deliver either increased energy or a good night’s sleep, will be available to U.S. consumers starting this month. A product of Los-Angeles based Khloros Innovation, a Canadian-based maker of chewable supplements, Chewpod is an efficient, easy-to-absorb product.
“We are looking forward to growing and expanding in the U.S. as we believe there is a great opportunity for functional gums and chewable tablets and their benefits especially knowing that global consumption of energy gum has grown an average of 6.6% every year for the past six years,” Joey Thiffault, president Chewpod, said. “The feedback we have received in the Canadian markets has been extraordinary. We believe that U.S. consumers will find the same satisfaction with our products.”
The Chewpod Energy On Demand functional gum is formulated with vitamins B6 and B5, caffeine, taurine and guarana seed extract. The Sleep on Demand SKU contains melatonin, vitamin B6 and natural amino acids to enhance total sleep time and quality, and help regulate the body’s natural sleep/wake cycle.
The Chewpod functional gum products are currently available for purchase on Chewpod.com and via Amazon. A single pack with four servings is $5. Bundles of four and bundles of 10 are also available for $18 and $40 respectively.
Available in the U.S. in two focus areas, the chewable supplement provides a beneficial effect on energy and ability to recover. Chewpod’s Fastactiv technology allows consumers to control their state of mind on demand, encouraging them to live every moment to the fullest regardless of the activity at hand.
Each pack of Chewpod comes with eight individually packaged, chewable, refreshing mint tablets. The Fastactiv technology delivers a pleasant energy quickly and is easily absorbed by the body.
All products are locally manufactured in North America and distributed exclusively in the United States and Canada.
CHPA conference highlights need for new avenues
The 2018 CHPA Annual Executive Conference, held last week at Turnberry Island north of Miami made news, provided the OTC industry with actionable insight, reorganized leadership, expanded its scope and honored one of its own. On the content side, the conference focused on the how to leverage disruption for innovation and growth.
There was a strong recurring theme throughout the conference; the OTC industry truly needs new growth avenues.
One of the staple industry presentations, IRI’s Changing Competitive and Retail Landscape, clearly showed slower growth and industry disrupters. The U.S. OTC industry reached $44 billion in revenues in 2017 (compared to the Rx market of $451Bn.) but recorded an anemic 5-year low 2.4% growth even with the strong flu season’s tailwinds. Even perhaps more surprising, U.S. OTC market growth outpaced Rx growth which came in at a recent low of 1.2%. Several ongoing growth trends — store-brand products, lack of major Rx-to-OTC switches and fewer innovative new products—all contributed. Meanwhile, brand owners had to continue to adjust to other unrelenting challenges, with drug chains visits dropping 6% and e-commerce’s share, now at 17% of consumer healthcare sales led by VMS and Weight Management, increasing. If the huge U.S. flu season impacting 10-12% of the country or over twice the 2016 rate hadn’t occurred, 2017 would have been a tough year for most conference attendees.
IRI did provide a roadmap for growth or at least focus areas. The overall trends point towards three core consumer groups providing growth potential: millennials, Boomers and Hispanics. And the go-to-market norms will be further disrupted by the continued growth of “click and collect” and the refinement of voice activation purchasing.
Within the CHPA vision and mission, CEO Scott Melville outlined several new CHPA initiatives and a new organizational structure. Notably, the trade group will now welcome non-Rx Medical Devices while reorganizing into three councils covering OTC Drugs, Supplements and now, Medical Devices. On the ongoing meeting front, the general Marketplace Exchange will be transitioned into two focused meetings: Marketing and Supply Chain.
Meanwhile, the industry’s long-desired Monograph Reform does seem to be gaining some traction in a difficult political environment. In a CHPA leadership discussion, Barbara Kochanowski, CHPA’s senior vice president of regulatory and scientific affairs, was quite positive about Food and Drug Administration commissioner Scott Gottlieb’s openness with the Policy Roadmap initiative providing clearer rules and a publicly available dashboard for tracking FDA progress on various issues. CHPA also is supporting a return for OTC eligibility within health savings accounts while continuing the industry’s long-standing consumer communication goals of safe usage, storage and disposal of OTCs.
CHPA also saw a changing-of-the-guard with the election of the CEO of Clarion Brands, Gary R. Downing replacing Jeffrey Needham, Perrigo executive vice president and president of U.S. consumer healthcare. Clarion is a Swander Pace Capital company and Downing brings 30+ years of domestic and international OTC experience. Lastly, the CHPA’s highest honor, the Ivan Combe Award was bestowed on John Hendrickson, the retiring CEO of Perrigo.
Ed Rowland is a Drug Store News Contributing Editor covering global issues. As the principal of Rowland Global LLC (www.rowland-global.com) he believes in the promise of global business and supports companies in their strategy, tactics and execution of international growth initiatives.
Dr. Reddy’s launches private label version of allergy remedy Xyzal
Princeton, N.J.-based Dr. Reddy’s Laboratories last week launched levocetirizine dihydrochloride tablets USP, 5 mg, an over-the-counter therapeutic equivalent private label version of Sanofi Consumer Health’s Xyzal Allergy 24HR Tablets in the United States market as approved by the U.S. Food and Drug Administration.
“This first-to-market launch for the store brand is the testament to the deep capabilities of our store brand OTC business,” Milan Kalawadia, vice president and head, U.S. OTC and speciality Rx businesses, Dr. Reddy’s Laboratories, said. “We look forward to collaborating with our customers to bring high-quality, affordable store brand alternatives to the market.”
The Xyzal generic equivalent is an over-the-counter antihistamine used for 24-hour relief of allergy symptoms such as watery eyes, runny nose, itching eyes/nose, and sneezing. The branded Xyzal Allergy 24HR Tablets had U.S. sales of approximately $71 million for the most recent 12 months ending in January 2018 according to IRI, Dr. Reddy’s reported.